Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ALA Topical Powder in Acne Vulgaris
NCT04044898Phase 1Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aminolevulinic acid 10% gel in acne vulgaris (2 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 5 more. Started Jan 2021; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04044898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044898.